Panacea Index Logo

Command Palette

Search for a command to run...

Soy lecithin reduces plasma lipoprotein cholesterol and early atherogenesis in hypercholesterolemic monkeys and hamsters: beyond linoleate.

Atherosclerosis
September 1, 1998
T A Wilson et al. (3 authors)
Journal ArticleAnimal Study
Study Details

Study Goal

The researchers aimed to investigate the hypocholesterolemic and anti-atherogenic properties of soy lecithin beyond its fatty acid content.

Results Summary

Soy lecithin significantly reduced plasma total cholesterol and non-HDL-C levels in monkeys and hamsters, with the mAHA Step I diet showing greater reductions than the AHA Step I diet. In hamsters, soy lecithin also markedly decreased aortic fatty streak area, indicating anti-atherogenic effects not solely attributable to its linoleate content.

Population

Cynomolgus monkeys (18) and hamsters (45).

Effective Dosage

3.4% soy lecithin in diet.

Duration

8 weeks.

Interactions

None mentioned.

Extracted Claims (16)
InterventionDirectionEndpointPopulationDosageImpactClaim #
modified AHA (mAHA) Step I diet containing 3.4% soy lecithin
decrease
plasma total cholesterol (TC)
cynomolgus monkeys
-46%
had significantly lower
#1
modified AHA (mAHA) Step I diet containing 3.4% soy lecithin
decrease
plasma non-HDL-C
cynomolgus monkeys
-55%
had significantly lower
#2
American Heart Association (AHA) Step I diet
decrease
plasma total cholesterol (TC)
cynomolgus monkeys
-21%
had lesser reductions in
#3
American Heart Association (AHA) Step I diet
decrease
plasma non-HDL-C
cynomolgus monkeys
-18%
had lesser reductions in
#4
modified AHA (mAHA) Step I diet containing 3.4% soy lecithin
decrease
plasma total cholesterol (TC)
cynomolgus monkeys
-32%
had significantly lower
#5
modified AHA (mAHA) Step I diet containing 3.4% soy lecithin
decrease
plasma non-HDL-C
cynomolgus monkeys
-45%
had significantly lower
#6
modified AHA (mAHA) Step I diet containing 3.4% soy lecithin
decrease
pre-treatment plasma total cholesterol (TC)
cynomolgus monkeys
-39%
significantly reduced
#7
modified AHA (mAHA) Step I diet containing 3.4% soy lecithin
decrease
pre-treatment plasma non-HDL-C
cynomolgus monkeys
-51%
significantly reduced
#8
modified AHA (mAHA) Step I diet containing 3.4% soy lecithin
no change
plasma HDL-C
cynomolgus monkeys
no significant change
no significant effect on
#9
modified AHA (mAHA) Step I diet containing 3.4% soy lecithin
no change
plasma triglyceride (TG)
cynomolgus monkeys
no significant change
no significant effect on
#10
HCD plus 3.4% soy lecithin (+SL)
decrease
plasma total cholesterol (TC)
hamsters
-58%
had significantly lower
#11
HCD plus 3.4% soy lecithin (+SL)
decrease
plasma non-HDL-C
hamsters
-73%
had significantly lower
#12
HCD plus 3.4% soy lecithin (+SL)
decrease
aortic fatty streak area
hamsters
-90%
had significantly lower
#13
HCD plus 3.4% soy lecithin (+SL)
decrease
plasma total cholesterol (TC)
hamsters
-33%
had significantly lower
#14
HCD plus 3.4% soy lecithin (+SL)
decrease
plasma non-HDL-C
hamsters
-50%
had significantly lower
#15
HCD plus 3.4% soy lecithin (+SL)
decrease
aortic fatty streak area
hamsters
-79%
significantly reduced
#16
Abstract

The current study was designed to investigate the hypocholesterolemic and anti-atherogenic properties of soy lecithin beyond its fatty acid content. In experiment 1, 18 cynomolgus monkeys were divided into three groups of six and fed diets which approximated either the average American diet (AAD), the American Heart Association (AHA) Step I diet, or a modified AHA (mAHA) Step I diet containing 3.4% soy lecithin for 8 weeks. Plasma samples were collected from food-deprived monkeys and analyzed for total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), very low- and low-density lipoprotein cholesterol (non-HDL-C), and triglyceride (TG) concentrations. Group comparisons revealed that monkeys fed the mAHA Step 1 diet had significantly lower plasma TC (-46%) and non-HDL-C (-55%) levels compared to the AAD diet, whereas monkeys fed the AHA Step 1 diet had lesser reductions in plasma TC (-21%) and non-HDL-C (-18%) levels. The monkeys fed the mAHA Step I diet had significantly lower plasma TC (-32%) and non-HDL-C (-45%) compared to the monkeys fed the AHA step diet. Also, only the mAHA Step I diet significantly reduced pre-treatment plasma TC and non-HDL-C levels by - 39 and -51% respectively with no significant effect on plasma HDL-C or TG levels. In experiment 2, 45 hamsters were divided into three groups of 15 and fed the following three modified non-purified diets for 8 weeks: a hypercholesterolemic diet (HCD) containing 10%, coconut oil and 0.05%, cholesterol, HCD plus 3.4%, soy lecithin (+SL), or the HCD with added levels of linoleate and choline equivalent to the +SL diet but no lecithin (-SL). Plasma lipids were determined as in experiment 1 and aortas were perfusion-fixed and Oil Red O stained for morphometric analyses of fatty streak area. Relative to the HCD group, the +SL-treated hamsters had significantly lower plasma TC (-58%), non-HDL-C (-73%) and aortic fatty streak area (-90%). Relative to the -SL group, hamsters fed the +SL diet had significantly lower plasma TC (-33%), non-HDL-C (-50%) and significantly reduced aortic fatty streak area (-79%). In conclusion, the first experiment suggests that the cholesterol-lowering efficacy of the AHA Step I diet can be enhanced with the addition of soy lecithin without reducing plasma HDL-C levels. whereas the second experiment suggest that the hypocholesterolemic, and in particular, the anti-atherogenic properties of soy lecithin cannot be attributed solely to its linoleate content.

Medical Subject Headings (MeSH)
AnimalsArteriosclerosisCholesterolCricetinaeDietary FatsDietary SupplementsHypercholesterolemiaLinoleic AcidMacaca fascicularisMalePhosphatidylcholinesSoybean Oil
Study Links
Quality Scores
SafetyNot Assessed
Efficacy85/10
Quality80/10
Citation Metrics
Total Citations56
Citations/Year2.1
Relative Citation Ratio1.65
NIH Percentile68.4%
Research Impact Scores
APT Score0.25
Weight Score0.45
Normalized Score0.70
Related Supplements